Patents by Inventor Marie Dutreix

Marie Dutreix has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of a combination of Dbait molecule and PARP inhibitors to treat cancer
    Patent number: 11162095
    Abstract: The present invention relates to the combination of a PARP inhibitor with a Dbait molecule for treating cancer.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: November 2, 2021
    Assignees: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ONXEO, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PARIS-SUD 11
    Inventors: Marie Dutreix, Wael Jdey
  • TREATMENT OF CANCER BY SYSTEMIC ADMINISTRATION OF DBAIT MOLECULES
    Publication number: 20210023116
    Abstract: The present invention relates to the use of a DBait molecules by systemic routes without any combination with an endosomolytic agent.
    Type: Application
    Filed: September 30, 2020
    Publication date: January 28, 2021
    Inventors: MARIE DUTREIX, NATHALIE BERTHAULT
  • A DBAIT MOLECULE AGAINST ACQUIRED RESISTANCE IN THE TREATMENT OF CANCER
    Publication number: 20200407720
    Abstract: The invention relates to a method for delaying and/or preventing development of cancer resistant to a cancer therapy agent in a patient based on administration of a Dbait molecule.
    Type: Application
    Filed: March 12, 2019
    Publication date: December 31, 2020
    Inventors: FRANÇOISE BONO, WAEL JDEY, MARIE DUTREIX
  • Treatment of cancer by systemic administration of Dbait molecules
    Patent number: 10821128
    Abstract: The present invention relates to the use of a DBait molecules by systemic routes without any combination with an endosomolytic agent.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: November 3, 2020
    Assignees: ONXEO, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Marie Dutreix, Nathalie Berthault
  • Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
    Patent number: 10765758
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: September 8, 2020
    Assignees: ONXEO, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jian-Sheng Sun, Marie Dutreix, Maria Quanz
  • USE OF A COMBINATION OF DBAIT MOLECULE AND PARP INHIBITORS TO TREAT CANCER
    Publication number: 20200172901
    Abstract: The present invention relates to the combination of a PARP inhibitor with a Dbait molecule for treating cancer.
    Type: Application
    Filed: February 14, 2020
    Publication date: June 4, 2020
    Inventors: MARIE DUTREIX, WAEL JDEY
  • Use of a combination of Dbait molecule and PARP inhibitors to treat cancer
    Patent number: 10563197
    Abstract: The present invention relates to the combination of a PARP inhibitor with a Dbait molecule for treating cancer.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: February 18, 2020
    Assignees: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ONXEO, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PARIS-SUD 11
    Inventors: Marie Dutreix, Wael Jdey
  • OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES
    Publication number: 20190314511
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Application
    Filed: July 1, 2019
    Publication date: October 17, 2019
    Inventors: JIAN-SHENG SUN, MARIE DUTREIX, MARIA QUANZ
  • Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
    Patent number: 10363317
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: July 30, 2019
    Assignees: ONXEO, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jian-Sheng Sun, Marie Dutreix, Maria Quanz
  • TREATMENT OF CANCER BY SYSTEMIC ADMINISTRATION OF DBAIT MOLECULES
    Publication number: 20190091254
    Abstract: The present invention relates to the use of a DBait molecules by systemic routes without any combination with an endosomolytic agent.
    Type: Application
    Filed: March 1, 2017
    Publication date: March 28, 2019
    Inventors: MARIE DUTREIX, NATHALIE BERTHAULT
  • USE OF A COMBINATION OF DBAIT MOLECULE AND PARP INHIBITORS TO TREAT CANCER
    Publication number: 20180362972
    Abstract: The present invention relates to the combination of a PARP inhibitor with a Dbait molecule for treating cancer.
    Type: Application
    Filed: July 22, 2016
    Publication date: December 20, 2018
    Inventors: MARIE DUTREIX, WAEL JDEY
  • OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES
    Publication number: 20170298089
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Application
    Filed: June 26, 2017
    Publication date: October 19, 2017
    Inventors: JIAN-SHENG SUN, MARIE DUTREIX, MARIA QUANZ
  • Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
    Patent number: 9687557
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: June 27, 2017
    Assignees: ONXEO, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jian-Sheng Sun, Marie Dutreix, Maria Quanz
  • OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES
    Publication number: 20160339107
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Application
    Filed: August 10, 2016
    Publication date: November 24, 2016
    Inventors: JIAN-SHENG SUN, MARIE DUTREIX, MARIA QUANZ
  • Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
    Patent number: 9428538
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: August 30, 2016
    Assignees: DNA THERAPEUTICS, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jian-Sheng Sun, Marie Dutreix, Maria Quanz
  • OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES
    Publication number: 20160046662
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Application
    Filed: October 27, 2015
    Publication date: February 18, 2016
    Inventors: JIAN-SHENG SUN, MARIE DUTREIX, MARIA QUANZ
  • Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
    Patent number: 9205099
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Grant
    Filed: June 21, 2011
    Date of Patent: December 8, 2015
    Assignees: DNA THERAPEUTICS, INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Jian-Sheng Sun, Marie Dutreix, Maria Quanz
  • Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia
    Patent number: 9205101
    Abstract: The present invention relates to a method for treating a cancer including a combination of a treatment by a nucleic acid molecule mimicking double strand breaks with hyperthermia.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: December 8, 2015
    Assignees: INSTITUT CURIE, DNA THERAPEUTICS
    Inventors: Marie Dutreix, Jian-Sheng Sun, Flavien Devun
  • CANCER TREATMENT BY COMBINING DNA MOLECULES MIMICKING DOUBLE STRAND BREAKS WITH HYPERTHERMIA
    Publication number: 20140100266
    Abstract: The present invention relates to a method for treating a cancer including a combination of a treatment by a nucleic acid molecule mimicking double strand breaks with hyperthermia.
    Type: Application
    Filed: May 25, 2012
    Publication date: April 10, 2014
    Applicants: DNA THERAPEUTICS, INSTITUT CURIE
    Inventors: Marie Dutreix, Jian-Sheng Sun, Flavien Devun
  • Optimized In Vivo Delivery System with Endosomolytic Agents for Nucleic Acid Conjugates
    Publication number: 20130131155
    Abstract: The present invention relates to an optimized in vivo delivery system with endosomolytic agents for nucleic acid of therapeutic interest conjugated to molecules facilitating endocytosis, in particular for use in the treatment of cancer.
    Type: Application
    Filed: June 21, 2011
    Publication date: May 23, 2013
    Applicants: DNA THERAPEUTICS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE
    Inventors: Jian-Sheng Sun, Marie Dutreix, Maria Quanz